• Users Online: 319
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 137-138

Ponatinib in chronic myeloid leukemia: Finally getting it right?


Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Date of Submission03-Jan-2020
Date of Acceptance03-Jan-2020
Date of Web Publication24-Feb-2020

Correspondence Address:
Bhausaheb Bagal
Department of Medical Oncology, Adult Hematolymphoid Unit, Tata Memorial Hospital, Mumbai, Maharashtra; Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_5_20

Get Permissions


How to cite this article:
Bagal B, Munot P. Ponatinib in chronic myeloid leukemia: Finally getting it right?. Cancer Res Stat Treat 2020;3:137-8

How to cite this URL:
Bagal B, Munot P. Ponatinib in chronic myeloid leukemia: Finally getting it right?. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Apr 7];3:137-8. Available from: http://www.crstonline.com/text.asp?2020/3/1/137/279145



We read with interest the article[1] by Jain et al. and wish to thank the authors for the comprehensive review. It seems that, despite having serious side effects, this drug has its place in the management of chronic myeloid leukemia (CML) in difficult to treat situations such as T315I or compound mutations. The side effect profile seems to resemble that of nilotinib rather than the other currently available tyrosine kinase inhibitor (TKI) in terms of cardiovascular events, hepatitis, and skin rash.[2] It will be interesting to see if these particular events were more common in patients exposed earlier to nilotinib. The potency of newer TKIs is relevant even in patients responding optimally to imatinib but who fail to achieve deep molecular remission (DMR). One may use more potent TKI to achieve DMRs with the ultimate goal of a treatment-free remission.[3] The serious nature of side effects makes ponatinib, an unlikely candidate in such a situation. Asciminib, a potent BCR-ABL1 inhibitor which targets the ABL1 myristoyl pocket, is being actively studied in CML and offers an opportunity to combine it with other TKI.[4] It is being studied in combination with other TKI; however, its combination with ponatinib seems difficult for safety reasons. We would like to have the comments of the authors on the same.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Jain H, Thorat J, Sengar M, Dubey A. Ponatinib: A drug review. Cancer Res Stat Treat 2019;2:190-6.  Back to cited text no. 1
  [Full text]  
2.
Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-40.  Back to cited text no. 2
    
3.
Hughes TP, Boquimpani C, Takahashi N, Benyamini N, Vasily S, Lipton JH, et al. HGENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with 18 chronic myeloid leukemia in chronic phase (CML-CP) after stopping 19 second-line (2L) nilotinib (NIL). J Clin Orthod 2019;37:7005.  Back to cited text no. 3
    
4.
Westerweel PE, Te Boekhorst PA, Levin MD, Cornelissen JJ. New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol 2019;9:665.  Back to cited text no. 4
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed111    
    Printed0    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal